The Effects of Adrenaline and Milrinone in Patients With Myocardial Dysfunction After CABG (AMORI)
Myocardial dysfunction necessitating inotropic support is a typical complication after on-pump cardiac surgery. This prospective, randomized pilot-study analyses the metabolic and renal effects of the inotropes adrenaline and milrinone in patients needing inotropic support after coronary-artery-bypass-grafting. With respect to data derived from patients with sepsis shock and results from studies using phosphodiesterase-inhibitors prophylactically, the hypothesis is tested that adrenaline may be associated with unwarranted metabolic effects (hyperlactatemia and hyperglycemia) and renal dysfunction.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Phase 3 Study of Adrenaline and Milrinone in Patients With Myocardial Dysfunction|
- Plasma lactate concentration in the immediate postoperative period
- Plasma pyruvate
- Plasma glucose
- Plasma creatinine
- Urinary excretion of alpha-1-microglobulin
- Plasma cystatin C
|Study Start Date:||June 2003|
|Study Completion Date:||April 2007|
|Primary Completion Date:||August 2004 (Final data collection date for primary outcome measure)|
Following preoperative written informed consent, patients presenting with a cardiac-index (CI) < 2.2 l/min/m2 upon ICU-admission - despite adequate mean arterial (titrated with noradrenaline or sodium-nitroprusside) and filling pressures - will be randomized to 14 hour treatment with adrenaline or milrinone to achieve a CI > 3.0 l/min/m2.
A group of patients not needing inotropes will be used as controls. Hemodynamics, metabolism (plasma lactate, pyruvate, glucose, acid-base status, insulin requirements) and renal function (urinary excretion of alpha-1-microglobulin, creatinine clearance, plasma cystatin-C levels) will be determined during the treatment period and up to 48 hours after surgery (follow up period).
The study is designed as a pilot study including 20 patients per group.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00446017
|Principal Investigator:||Matthias Heringlake, MD||Department of Anesthesiology, University of Luebeck|